hVIVO plc (AIM: HVO), a specialist contract research organisation (CRO) in infectious disease testing, has announced positive topline results from a Phase 2a Respiratory Syncytial Virus (RSV) human challenge trial for Enanta Pharmaceuticals' antiviral candidate EDP-323. This trial involved 142 healthy adult volunteers and demonstrated significant antiviral efficacy.
Participants were divided into three groups - high dose, low dose and placebo. Results indicated that EDP-323 achieved an 85-87% reduction in viral load as measured by qRT-PCR, a 97-98% reduction in infectious viral load via viral culture, and a 66-78% decrease in total clinical symptoms score, all with p-values less than 0.0001.
The successful outcomes underscore the value of human challenge trials in expediting efficacy data and mitigating risks in later-stage clinical development. With over 30 years of experience, hVIVO supports crucial research across various respiratory viruses, including RSV and COVID-19.
EDP-323, an oral antiviral, has received U.S. Food and Drug Administration (FDA) Fast Track designation.
Enanta's first RSV candidate, Zelicapavir (EDP-938), has also shown promising results in prior trials.
hVIVO operates from its state-of-the-art facilities in Canary Wharf, London, the world's largest commercial human challenge trial unit, equipped with advanced virology and immunology laboratories. The Group offers a comprehensive suite of early clinical development services, maintaining partnerships with four of the top ten global biopharma companies.
IDEAYA announces IDE034 as development candidate; Secures global license from Biocytogen
ANGLE plc highlights dual CTC and ctDNA analysis in NSCLC research
Mabwell announces promising pre-clinical Data of 7MW4811 at the 15th World ADC Conference
Dizal submits NDA to US FDA for sunvozertinib in treating NSCLC with EGFR exon 20 mutations
Harbour BioMed submits IND application for HBM9378/SKB378 in COPD treatment
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant
Merck and Moderna launch new Phase 3 trial for cancer vaccine